European Registry on the Management of Helicobacter Pylori Infection
Key facts
- Who runs it
- Javier P. Gisbert
- Where
- Austria, Belgium, Bulgaria, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Spain, Sweden, Switzerland, Türkiye, Ukraine, and United Kingdom30 sites in 30 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- Jun 2013
- Expected to end
- Dec 2034
- Type of study
- Observational
- Record updated
- 2 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show the criterionShow less
Who can take part
- Infected adult patients by Helicobacter pylori
This trial has no sites in United States.
It has sites in 30 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency.
Read full original descriptionShow less
Primary aim
To obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection.
Secondary aims
1. To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries. 2. To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori. 3. To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection. 4. To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee
Methodology Non-interventionist prospective multicentre international registry promoted by the European Helicobacter Study Group. A renowned gastroenterologist from each country was selected as Local Coordinator (30 countries). They will in turn select up to ten gastroenterologists per country that will register the routine clinical practice consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome data. The database will allow researchers to perform specific subanalysis after approval by the Scientific Committee of the study.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Higher Doses of Bismuth and Antibiotics Do Not Improve Helicobacter pylori Treatment Effectiveness: Results From the European Registry on Helicobacter pylori Management.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026
- Real-World Effectiveness and Safety of Saccharomyces boulardii CNCM I-745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp-EuReg).Helicobacter, 2026
- Long-Term Effect of Macrolides on Helicobacter pylori Eradication: Data From the European Registry on Helicobacter pylori Management (Hp-EuReg).Helicobacter, 2026
- Lack of Usefulness of Literature-Based Helicobacter pylori Resistance Data for Predicting First-Line Empirical Treatment Effectiveness in the European Registry on H. pylori Management (Hp-EuReg).Helicobacter, 2026
- Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg).The American journal of gastroenterology, 2025
- Second- and Third-Line Therapies for Helicobacter pylori Eradication in Slovenia: Data From 2013-2023 of the European Registry on H. pylori Management.Helicobacter, 2025
- Management of Helicobacter pylori Infection in Spain Beyond the Data Collected in the European Registry on H. pylori Management (Hp-EuReg): Results of a Nationwide Survey.Helicobacter, 2025
- First-Line Therapy for Helicobacter pylori in Slovenia: Data From 2013 to 2023 of the European Registry on H. pylori Management.Helicobacter, 2025
- Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg).Gut, 2024
- Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).Helicobacter, 2024
- Record updated
- 2 October 2024